Nurix Therapeutics, Inc.
NRIX Healthcare Biotechnology
Nurix Therapeutics, Inc.’s revenue for fiscal 2025 (year ended November 2025) was $84.0 million, up 54.0% from fiscal 2024. In the quarter to August 2026, revenue grew 8,426.3%, EPS grew 578.5% and free cash flow grew 1,122.1%, each against the same quarter a year earlier.
Follow NRIX
Nurix Therapeutics, Inc. (NRIX) EV/Sales
As of 16 October 2026, Nurix Therapeutics, Inc. (NRIX) trades at a EV/Sales of 2.4×. Over the past ten years it has ranged from −0.4× (October 2023) to 74.1× (March 2021); the current reading is higher than 7% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 10.4× | (31.94%) |
| FY2024 | 15.3× | 2,247.40% |
| FY2023 | 0.7× | (91.43%) |
| FY2022 | 7.6× | (76.00%) |
| FY2021 | 31.6× | 45.63% |
| FY2020 | 21.7× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Aug 2026 | 2.6× | (93.57%) |
| May 2026 | 40.5× | 142.22% |
| Feb 2026 | 16.7× | 60.83% |
| Nov 2025 | 10.4× | 157.37% |
| 24 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CELC Celcuity, Inc. compare | n/m |
| DYN Dyne Therapeutics, Inc. compare | n/m |
| ELVN Enliven Therapeutics, Inc. compare | n/m |
| NRIX Nurix Therapeutics, Inc. | 2.4× |
| ZLAB Zai Lab Limited Unsponsored ADR compare | 4.7× |
| DNLI Denali Therapeutics Inc. compare | 8.6× |
| BEAM Beam Therapeutics Inc. compare | 8.9× |
| RCUS Arcus Biosciences, Inc. compare | 18.7× |
| PGEN Precigen, Inc. compare | 27.2× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)